Features of clinical manifestations of coronary heart disease in patients with amiodarone-associated hypothyroidism

Abstract

Coronary heart disease (CHD) is an acute problem of modern medicine. Primarily, it is determined by the high prevalence of the disease among the working-age population, as well as by the considerable mortality and disability associated with it. Amiodarone (Am) is the drug of choice in the treatment of cardiac arrhythmias (CA), one of the frequent and threatening manifestations of CHD. Long-term use of the drug can lead to the development of primary hypothyroidism (HT), which significantly aggravates the course of cardiovascular diseases. Objective. To assess the cardiovascular system (CVS) of CHD patients with the development of amiodarone-associated hypothyroidism (AmHT). Material and methods. Analysis of case histories of 810 patients with CHD and various CA who were taking Am for sinus rhythm control was performed. The case histories were examined and a retrospective analysis was performed on the clinical course of CHD in 28 patients with AmHT before and after the development of thyreopathy. To evaluate the state of cardiovascular system the patients' complaints, objective examination data, electrocardiography (ECG) and echocardiography (EchoCG) were assessed. Results. Long-term intake of Am by patients with CHD results in primary HT in 3.4% of cases. The formation of thyreopathy significantly affects the course of the disease. Patients show a 19.6% increase in myocardial volume indices and a 22.7% decrease in myocardial contractility, with a 30.2% increase in left ventricular myocardial mass (LVMM). Conclusion. Amiodarone-associated hypothyroidism is one of the significant complications developing in patients taking the drug for a long period of time. The formation of thyreopathy in patients with CHD significantly aggravates the course of the underlying disease, which should be taken into account when prescribing treatment and dynamic monitoring